Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

87.68 -1.41 (-1.58%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
58 59 Next >
News headline image
2 Healthcare Stocks That Tumbled in 2024...but Could See an Impressive Comeback in 2025 ↗
Via The Motley Fool
News headline image
AstraZeneca's Imfinzi Perioperative Regimen Shows Improved Survival Outcomes In Bladder Cancer Patients ↗
AstraZeneca's Imfinzi perioperative regimen improved survival outcomes in muscle-invasive bladder cancer, with FDA Priority Review expected in Q2 2025. 
Via Benzinga
News headline image
Is NASDAQ:AZN suited for quality investing? ↗
A fundamental analysis of (NASDAQ:AZN): Is ASTRAZENECA PLC-SPONS ADR (NASDAQ:AZN) a Strong Candidate for Quality Investing? 
Via Chartmill
News headline image
Why Is Rare Disease Focused Ascendis Pharma Stock Trading Higher On Thursday? ↗
Ascendis Pharma beat Q4 earnings and revenue estimates, driven by a $100M Novo Nordisk deal and Yorvipath's EU launch. Goldman Sachs raised its price target. 
Via Benzinga
News headline image
This AstraZeneca Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday ↗
 
Via Benzinga
News headline image
Why AstraZeneca Topped the Market on Thursday ↗
Via The Motley Fool
News headline image
AstraZeneca Unusual Options Activity ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 6, 2025 ↗
 
Via Benzinga
News headline image
Trade Desk, Leidos, Devon Energy And A Major Health Care Stock On CNBC's 'Final Trades' ↗
 
Via Benzinga
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
AstraZeneca Plc (AZN) Q4 2024 Earnings Call Transcript ↗
AZN earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
AstraZeneca Bounds Higher On Fourth-Quarter Beat, Upbeat Guidance ↗
AstraZeneca stock rose early Thursday after the drugmaker beat fourth-quarter earnings views and delivered upbeat guidance. 
Via Investor's Business Daily
News headline image
AstraZeneca Q4 Earnings: Revenue And EPS Beat On Higher Cancer And Respiratory Drug Sales, Faces $4.5 Million Potential Fine In China ↗
AstraZeneca's Q4 revenue beat estimates at $14.89 billion, with strong oncology sales. China sales dipped 1%, while FY25 guidance forecasts solid growth. 
Via Benzinga
News headline image
Arcutis Soared In 2024, Blazing Trails In Dermatology. Why Its CEO Eyes Bigger Gains. ↗
The company won three FDA approvals over the past two years. Now, it's angling for two new approvals in 2025. 
Via Investor's Business Daily
News headline image
Q4 Earnings Scorecard & Analyst Reports For Alphabet, Blackstone & KLA ↗
Today's Research Daily features a real-time scorecard of the Q4 earnings season and new research reports on 16 major stocks, including Alphabet Inc., Blackstone Inc., and KLA Corporation, as well as a... 
Via Talk Markets
Topics Stocks / Equities
News headline image
AstraZeneca Blames 'Toxic' Climate As It Walks Away from Over $550 Million UK Vaccine Plant ↗
AstraZeneca scrapped plans for a £450 million UK vaccine plant after rejecting a £78 million government offer, citing concerns over NHS drug pricing and industry tensions. 
Via Benzinga
News headline image
RFK Jr. And Big Pharma: Health Secretary Hopeful Answers Pointed Questions On Drugs, Insurance, Trump Exec Orders ↗
Kennedy seeks to be Secretary of Health and Human Services — a position that would put him in charge of the health of the American people. 
Via Benzinga
Topics Government
News headline image
FDA Approves AstraZeneca, Daiichi Sankyo's Enhertu For Certain Type Of Breast Cancer Patients ↗
FDA approves Enhertu for metastatic breast cancer with HER2-low or HER2-ultralow expression after showing significant efficacy in the DESTINY-Breast06 trial. 
Via Benzinga
News headline image
AstraZeneca To Pump $570 Million Into Canada, Driving Expansion, Job Growth ↗
AstraZeneca invests $570 million in Canada, expands facilities, and boosts R&D efforts, aiming to deliver 20 new medicines globally by 2030. 
Via Benzinga
News headline image
Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst ↗
Cytokinetics receives a Buy rating from Stifel, with a promising outlook for aficamten in the $3 billion U.S. oHCM market, despite investor concerns over M&A and deals. 
Via Benzinga
News headline image
Analyst Praises AMD-Partner Absci's Practical Approach, Sees 118% Stock Upside ↗
Needham initiated a Buy rating for Absci (ABSI), noting its AI-powered drug discovery platforms, strategic partnerships, and $9 price target. 
Via Benzinga
News headline image
FDA Approves AstraZeneca's Datroway For Pretreated Breast Cancer Patients ↗
AstraZeneca's Datroway gains FDA approval for HR-positive, HER2-negative breast cancer after prior therapies, based on Phase 3 trial data. 
Via Benzinga
News headline image
Beyond Rigetti: Top 3 Quantum Computing Stock Picks
Quantum computing is in its early stages, but investors may benefit from the incremental progress being made by these three companies 
Via MarketBeat
Topics Artificial Intelligence
News headline image
3 Unstoppable Dividend-Growth Stocks Yielding More Than 3% That Income-Seeking Investors Want to Buy in 2025 and Hold Forever ↗
Via The Motley Fool
News headline image
AstraZeneca Aims to Restore Trust With New Leadership in China Amid Scandal and Sales Decline ↗
AstraZeneca restructures its China operations following leadership scandals and sales challenges, appointing new executives and focusing on innovative cancer drugs. 
Via Benzinga
News headline image
Popular Ozempic, Wegovy Selected For Next Round Of Medicare Drug Price Negotiations ↗
HHS adds 15 drugs to Medicare Part D price negotiations, targeting cost reductions under the Inflation Reduction Act. New prices aim to save billions by 2027. 
Via Benzinga
Topics Economy
News headline image
FDA Approves AstraZeneca's Calquence Combo Therapy For Untreated Mantle Cell Lymphoma ↗
AstraZeneca's Calquence gains FDA approval for untreated mantle cell lymphoma, supported by data showing improved survival and reduced disease progression. 
Via Benzinga
News headline image
3 High-Yielding Dividend Stocks That Are Trading at Dirt Cheap Prices ↗
Via The Motley Fool
News headline image
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts. ↗
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up. 
Via Investor's Business Daily
Topics Artificial Intelligence Government
News headline image
3 Cheap Growth Stocks to Buy in 2025 ↗
Via The Motley Fool
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
58 59 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.